Free Trial
NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

$1.39
+0.02 (+1.46%)
(As of 05/21/2024 ET)
Today's Range
$1.37
$1.46
50-Day Range
$1.29
$1.57
52-Week Range
$1.26
$2.66
Volume
20,078 shs
Average Volume
46,282 shs
Market Capitalization
$68.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MediciNova MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of MediciNova in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.23) to ($0.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.26 out of 5 stars

Medical Sector

891st out of 920 stocks

Pharmaceutical Preparations Industry

402nd out of 413 stocks

MNOV stock logo

About MediciNova Stock (NASDAQ:MNOV)

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MNOV Stock Price History

MNOV Stock News Headlines

StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)
Medicinova Inc
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2023
Today
5/21/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MNOV
Employees
13
Year Founded
2000

Profitability

Net Income
$-8,560,000.00
Pretax Margin
-840.50%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.27 per share

Miscellaneous

Free Float
41,738,000
Market Cap
$68.18 million
Optionable
Optionable
Beta
0.70

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Yuichi Iwaki M.D. (Age 74)
    Ph.D., Co-Founder, President, CEO & Executive Director
    Comp: $933.05k
  • Dr. Kazuko Matsuda M.D. (Age 58)
    M.P.H., Ph.D., Chief Medical Officer & Director
    Comp: $653.65k
  • Mr. Jason J. Kruger CPA (Age 46)
    CFO & Principal Financial Officer
  • Dr. David H. Crean M.B.A. (Age 59)
    Ph.D., Chief Business Officer
  • Mr. John O'Neil CPA
    Controller

MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed in 2024?

MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV stock has decreased by 7.3% and is now trading at $1.39.
View the best growth stocks for 2024 here
.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our MNOV earnings forecast
.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) posted its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01.

What other stocks do shareholders of MediciNova own?
How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MNOV) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners